$10,351.13 consulting Payment -- Johnson & Johnson to Dr. Eric Sanchez

General Surgeon Eric Sanchez Receives $10,351 Consulting Fee from Johnson & Johnson

This page provides a detailed analysis of a $10,351.13 consulting payment from Johnson & Johnson to Dr. Eric Sanchez. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$10,351.13
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyJohnson & Johnson
PhysicianDr. Eric Sanchez
NPI Number1620229610
Physician SpecialtyGeneral Surgery
LocationSan Antonio, TX
Date of Payment2025-05-27
Related Drug/DeviceOzempic
Conflict AssessmentModerate -- Worth Noting

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Johnson & Johnson made a $10.4K consulting payment to Eric Sanchez, a General Surgery specialist in San Antonio, TX. The payment was associated with Ozempic. Eric Sanchez received a $10,351.13 consulting fee from Johnson & Johnson on May 27, 2025. The payment was related to consulting services, not directly tied to a specific drug or device in the record. This payment falls under the 'consulting' category, which can involve advising on research, product development, or market insights.

Patient Guidance: What This Payment Means for You

Patients should be aware that their healthcare providers may receive payments from pharmaceutical companies for consulting services, which are publicly disclosed. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees for physicians can vary widely based on expertise and the scope of work, but this amount is notable for a single engagement in General Surgery.

Regulatory Context: Sunshine Act Requirements

Payments to physicians from manufacturers are regulated under the Sunshine Act, requiring disclosure of such financial relationships to ensure transparency.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $10.4K payment for?

This was a consulting payment of $10.4K from Johnson & Johnson to Eric Sanchez, categorized as "Consulting Fee". It was associated with Ozempic. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Eric Sanchez accept pharmaceutical money?

Yes, Eric Sanchez received this $10.4K payment from Johnson & Johnson. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Eric Sanchez's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $10.4K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in General Surgery?

To compare this payment against General Surgery averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. General Surgery physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Eric Sanchez's relationship with Johnson & Johnson?

The payment amount is substantial for a single consulting engagement. This $10.4K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for General Surgery?

The payment date is in the future, suggesting it may be a pre-arranged agreement.

What should patients do after learning about this payment?

Patients should be aware that their healthcare providers may receive payments from pharmaceutical companies for consulting services, which are publicly disclosed.

What else should I know about this consulting payment?

The record specifies 'Consulting Fee' as the nature of the payment.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.